Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 14c

May 10, 2022 7:37 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q1 EPS of ($0.78), $0.14 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $35 million versus the consensus estimate of $33.65 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

The Children's Investment Fund (TCI), Earnings